RSS worker’s murder: Cops illegally detaining innocent Muslims, says SDPI

Bengaluru, May 27: Amid uncertainty caused by the Covid-19 pandemic, which has disrupted school education in Karnataka, the state government is seeking the help of the Union Ministry of Information and Broadcasting to televise classes, a state minister said on Tuesday.

"We request you to provide minimum three channels on the Doordarshan network exclusively for the Department of Public Instruction, Government of Karnataka," Primary and Secondary Education Minister Suresh Kumar said in a letter to Union I&B Minister Prakash Javadekar.

Suggesting co-branding the channels under DD and the state education department, he asked for the channels to be mandatorily transmitted by the cable and DTH operators under the Cable Act.

The state education department has already discussed with Prasar Bharti officials, who, according Kumar, have assured 3+3 hours of timeslots on the education channel Chandana on cost basis.

"We have also made all the necessary arrangements for content creation by the teachers," he said.

Meanwhile, the minister has revealed that television is the best medium for the students as a home learning mode in these challenging times.

"The department of public instruction reviewed various technological options and considered TV as one of the best means for home learning," Kumar said.

In a survey conducted by the education department, it was found out that 95 per cent households had television sets.

Kumar said the state operates government schools in nine languages, including Kannada, English and Urdu.

"To cater to all the students, and considering a long-term strategy to run schools by maintaining social distancing, we are in immediate need of minimum three exclusive channels to teach through TV," he said.

According to Kumar, the Karnataka government is facing hardships to meet the capital expenditure requirements, hence, it is seeking help from the I&B Ministry.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Bengaluru, Feb 28: Bengaluru Police Commissioner Bhaskar Rao on Friday said that Section 144 will be imposed near Vidhana Soudha for Budget session starting from March 2.

"Section 144 of the CrPC (prohibits assembly of more than 4 people in an area) will be imposed in the area around Vidhana Soudha from March 2 to March 31 ahead of the Budget session,"Bhaskar Rao said.

The police said that they have intelligence inputs of protests near Vidhana Soudha.